Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population

Dipeptidyl peptidase-4 inhibitorshave been suspected to induce bullous pemphigoid(BP). The objective of this study was to compare the observed frequency of gliptin intake in a large sample of 1,787 BP patients diagnosed between 2012 and 2015 in France, with the expected frequency after indirect age standardization on 225,412 individuals extracted from the database of the National Healthcare Insurance Agency. The secondary objective was to assess the clinical characteristics and the course of gliptin-associated BP, depending on whether gliptin was continued or stopped. The observed frequencies of intake of the whole gliptin class and that of vildagliptinin the BP population were higher than those in the general population after age standardization (whole gliptin class: 6.0%; 95% confidence interval= 4.9–7.1% vs. 3.6%, observed-to-expected drug intake ratio = 1.7; 95% confidence interval= 1.4–2.0; P P P